Related Experiment Video
Updated: Mar 13, 2026

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
Antithrombin III as a potentially predictive biomarker for post-stroke depression
Fengyun Wang1, Yongtao Yu2, Xiaoxuan Zhang3
1Department of Neurology, the Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, 214023, China.
Insights
Antithrombin III (ATIII) activity changes during stroke treatment may predict post-stroke depression (PSD). Higher ATIII levels correlate with increased depressive symptoms and inflammation in PSD patients, indicating its potential as a biomarker.
Area of Science:
- Neuroscience
- Immunology
- Biochemistry
Background:
- Antithrombin III (ATIII) possesses anti-inflammatory properties beyond its role in coagulation.
- Post-stroke depression (PSD) is a common complication following ischemic stroke.
Purpose of the Study:
- To investigate the association between Antithrombin III (ATIII) and post-stroke depression (PSD).
- To evaluate ATIII's potential as a predictive biomarker for PSD.
Main Methods:
- A longitudinal observational study enrolled 120 PSD patients and 100 ischemic stroke controls.
- Clinical parameters, including ATIII activity, were assessed during hospitalization.
- PSD patients underwent psychological assessments (HAMD-24) at 3, 9, and 15 months post-discharge.
Main Results:
- PSD patients showed significantly higher changes in ATIII activity compared to controls.
- Increased ATIII activity changes correlated with higher HAMD-24 scores and increased pro-inflammatory markers.
- ATIII levels interacted with C-reactive protein to influence depressive symptom severity.
Conclusions:
- Elevated ATIII activity during stroke treatment may predict PSD risk.
- Higher ATIII levels are linked to more severe depressive symptoms and inflammation in PSD patients.
- ATIII shows potential as a biomarker for predicting and assessing PSD severity.
Background:
Beyond its primary roles in coagulation and hemostasis, Antithrombin III (ATIII) demonstrates anti-inflammatory properties. This study aimed to investigate the association between ATIII and post-stroke depression (PSD) in a longitudinal observational study and to evaluate the clinical potential of ATIII as a predictive biomarker for PSD.
Method:
We enrolled 120 PSD patients and 100 ischemic stroke controls. Clinical parameters, including ATIII activity, were collected during hospitalization. PSD patients underwent psychological assessments at 3, 9, and 15 months post-discharge. Furthermore, 50 PSD patients provided additional blood samples at 15 months for ATIII concentration analysis.
Results:
Firstly, PSD patients exhibited significantly higher changes in ATIII activities from baseline to post-treatment than controls. Changes in ATIII activities showed an area under the curve of 0.724 to distinguish PSD patients from controls. Secondly, increased changes in ATIII activities during hospitalization were significantly associated with 24-item Hamilton Depression Scale (HAMD-24) scores at 3, 9, and 15 months of follow-up in PSD patients, as well as the changed rate of HAMD-24 scores during follow-up. Thirdly, quantified plasma concentration of ATIII were positively correlated with the HAMD-24 scores and plasma levels of pro-inflammatory factors in PSD patients. Fourthly, plasma ATIII concentration or changes in ATIII activities interacted with C-reactive protein levels to influence the HAMD-24 scores in PSD patients.
Conclusion:
Increased ATIII activity during stroke treatment may predict PSD risk. Higher ATIII levels associate with more severe depressive symptoms and enhanced inflammatory responses in PSD patients, suggesting its potential as a PSD biomarker.
More Related Videos
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Acute Coronary Syndrome III: Diagnostic Studies
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pulmonary Embolism III: Nursing Management

